Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee bought 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $14.48 per share, for a total transaction of $101,360.00. Following the acquisition, the chief executive officer owned 1,551,613 shares of the company’s stock, valued at $22,467,356.24. This represents a 0.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Tien-Li Lee also recently made the following trade(s):

• On Monday, September 15th, Tien-Li Lee purchased 10,000 shares of Aardvark Therapeutics stock. The shares were purchased at an average cost of $9.66 per share, with a total value of $96,600.00.

Aardvark Therapeutics Stock Down 7.6%

Shares of AARD stock traded down $1.18 during mid-day trading on Friday, hitting $14.43. 267,186 shares of the stock traded hands, compared to its average volume of 207,122. The company’s 50-day simple moving average is $11.93 and its 200-day simple moving average is $11.70. Aardvark Therapeutics, Inc. has a twelve month low of $4.88 and a twelve month high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Wall Street Analysts Forecast Growth

AARD has been the topic of several recent research reports. William Blair initiated coverage on shares of Aardvark Therapeutics in a research note on Friday. They issued an “outperform” rating on the stock. Royal Bank Of Canada dropped their price target on Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 14th. Raymond James Financial initiated coverage on Aardvark Therapeutics in a research note on Tuesday, December 2nd. They set a “strong-buy” rating and a $47.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Monday. Finally, Bank of America decreased their price target on Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.44.

Institutional Trading of Aardvark Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Cantor Fitzgerald L. P. grew its stake in shares of Aardvark Therapeutics by 26.1% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 96,682 shares of the company’s stock valued at $1,285,000 after buying an additional 20,000 shares in the last quarter. Laurion Capital Management LP lifted its stake in Aardvark Therapeutics by 6.1% in the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after acquiring an additional 60,653 shares during the last quarter. Millennium Management LLC bought a new stake in Aardvark Therapeutics in the third quarter worth approximately $4,248,000. Citadel Advisors LLC lifted its stake in shares of Aardvark Therapeutics by 5.9% in the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock valued at $18,073,000 after purchasing an additional 76,151 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Aardvark Therapeutics by 199.5% in the third quarter. Bank of America Corp DE now owns 23,930 shares of the company’s stock worth $318,000 after purchasing an additional 15,941 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.